Gene Knowledge Graph
UTC
Standard

CYP2C19 *17 — increased enzyme activity

CYP2C19 · rs12248560

Where this position leads

Condition: CYP2C19 Metaboliser Status

Drugs: Brivaracetam, Clopidogrel, Proton pump inhibitors, Serotonin reuptake antidepressants, Voriconazole

rs12248560 Condition: CYP2C19 Metaboliser Status CYP2C19 Metaboliser Status Condition Drug: Brivaracetam Brivaracetam Drug Drug: Clopidogrel Clopidogrel Drug Drug: Proton pump inhibitors Proton pump inhibitors Drug Drug: Serotonin reuptake antidepressants Serotonin reuptake antidepressants Drug Drug: Voriconazole Voriconazole Drug Topic: Heart and circulation Heart and circulation Topic rs12248560 rs12248560 CYP2C19

Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.

What ClinVar records

Classification drug response for CYP2C19: increased function, Clopidogrel response; practice guideline (4 of 4 stars, 4 submitters). ClinVar record 39357 NM_000769.1(CYP2C19):c.-806C>T

What this is ClinVar's aggregate record for this position (as of its 2026-10-19 release), not a result about you. A classification describes the variant against the condition named, as laboratories submitted it. Whether a person carries this variant, and what that would mean for them, is a question for a clinical test and a genetic counsellor.

What each result means

C/C No copy of *17.
C/T One copy of CYP2C19*17, a promoter variant associated with increased enzyme activity rather than less. It sits on the other side of the same dial: more activation of prodrugs such as clopidogrel, and faster clearance of drugs the enzyme inactivates.
T/T Two copies of CYP2C19*17 — the ultrarapid end of the range. Guidelines treat this as normal-to-increased for clopidogrel; where it matters more is for drugs CYP2C19 breaks down rather than switches on.
This is a pharmacogenomic result with a published dosing guideline behind it. Tell a prescriber or pharmacist rather than acting on it — and never stop or change a prescribed medicine on the strength of a genotype.
Source
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, Kisor DF, Limdi NA, Lee YM, Scott SA, Hulot JS, Roden DM
and 5 more — show all
Gaedigk A, Caudle KE, Klein TE, Johnson JA, Shuldiner AR
Clinical pharmacology and therapeutics · 2022 · PMID 35034351

What people read about alongside this

Heart and circulation5 Depression and stress2 Kidneys1

Papers in Europe PMC whose title or abstract names both this rsID and that subject. A shared paper means somebody wrote about the two together — it is not a claim that this position explains the subject.

Questions about rs12248560

What is rs12248560?

rs12248560 is a single position in the genome, in or near the CYP2C19 gene. Published research associates it with cyp2c19 *17 — increased enzyme activity. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

What conditions is rs12248560 linked to?

On MyGeneLog this position is linked to CYP2C19 Metaboliser Status. The research behind each link, and its sources, are set out on that condition page.

Does rs12248560 affect how medicines work?

CYP2C19 carries pharmacogenomic findings for Brivaracetam, Clopidogrel, Proton pump inhibitors, Serotonin reuptake antidepressants, Voriconazole. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.

What do people read about alongside rs12248560?

Subjects that appear in the title or abstract of the same papers as this rsID include heart and circulation (5 papers), depression and stress (2 papers), kidneys (1 papers). A shared paper means somebody wrote about the two together; it is not a claim that this position explains the topic.

Does having rs12248560 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs12248560 come from?

CPIC Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update, Clinical Pharmacology & Therapeutics (PMID 35034351). Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

Quoting this page

Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.

CYP2C19 *17 — increased enzyme activity (rs12248560). MyGeneLog™. https://www.mygenelog.com/variants/rs12248560

← See all variants